Actively Recruiting
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
Led by Mandana Kamgar, MD · Updated on 2026-05-05
80
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to better understand treatment outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) whose tumors have a specific KRAS G12R mutation. It focuses on evaluating the safety and effectiveness of different therapies involving mitogen-activated protein kinase kinase inhibitors (MEKi) combined with other treatments. The study also assesses whether it is feasible to conduct future clinical trials using these combination therapies. The study observes patients receiving one of several treatment approaches: therapy without MEKi, therapy combining MEKi with hydroxychloroquine (HCQ), therapy combining MEKi with an epidermal growth factor receptor inhibitor (EGFRi), or other MEKi-based combination therapies. Patients' tumor mutations are confirmed through molecular testing such as next-generation sequencing or circulating tumor DNA panels chosen by their doctors. Treatments are administered as part of the patients' standard care, and data is collected both retrospectively and prospectively. Participants provide medical records and undergo molecular profiling to track tumor response, survival rates, and any treatment-related side effects. Researchers analyze these outcomes over time, including the number of patients without disease progression at six months and responses or adverse events over two years. The study continues until 2027 and involves reviewing patient outcomes to guide future therapy strategies and clinical trial planning for this patient group.
CONDITIONS
Brief Title
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of advanced pancreatic ductal adenocarcinoma confirmed by physician or tumor board
- Tumor must have KRAS G12R mutation confirmed by next generation sequencing or circulating tumor DNA panel
- Ability to understand and sign informed consent
You will not qualify if you...
- Age under 18 years
- Primary cancer diagnosis other than advanced pancreatic ductal adenocarcinoma
- Tumor does not have KRAS G12R mutation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years
Participants' medical records are examined retrospectively and prospectively to analyze tumor response, survival, and toxicity related to their therapy.
Data collected through medical record reviews and routine clinical visits
Trial Site Locations
Total: 1 location
1
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
Research Team
M
Mandana Kamgar, MD, MPH
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here